Certara (NASDAQ:CERT) Hits New 12-Month Low – What’s Next?

Shares of Certara, Inc. (NASDAQ:CERT) hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $7.90 and last traded at $7.8450, with a volume of 1090826 shares trading hands. The stock had previously closed at $8.30.

Analyst Ratings Changes

Several analysts have issued reports on the company. KeyCorp dropped their target price on Certara from $13.00 to $12.00 and set an “overweight” rating on the stock in a research report on Thursday, January 8th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Certara in a research report on Monday, December 29th. Morgan Stanley reduced their target price on shares of Certara from $16.00 to $12.00 and set an “equal weight” rating for the company in a report on Thursday, December 18th. Barclays lowered their price target on shares of Certara from $14.00 to $13.00 and set an “overweight” rating on the stock in a report on Monday, December 15th. Finally, Rothschild Redb raised shares of Certara to a “strong-buy” rating in a research report on Friday, November 21st. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $12.58.

Certara Price Performance

The stock’s 50 day simple moving average is $9.19 and its 200-day simple moving average is $10.36. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.09 and a current ratio of 2.09. The firm has a market cap of $1.23 billion, a price-to-earnings ratio of 110.71 and a beta of 1.46.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.03. The firm had revenue of $104.62 million for the quarter, compared to analyst estimates of $104.53 million. Certara had a net margin of 2.62% and a return on equity of 5.18%. During the same period in the previous year, the company earned $0.13 earnings per share. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. Equities research analysts anticipate that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Institutional Investors Weigh In On Certara

A number of large investors have recently bought and sold shares of CERT. AQR Capital Management LLC acquired a new stake in Certara during the 1st quarter valued at approximately $259,000. Goldman Sachs Group Inc. boosted its holdings in Certara by 65.6% in the first quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company’s stock valued at $2,267,000 after purchasing an additional 90,724 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Certara by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company’s stock worth $2,965,000 after purchasing an additional 35,954 shares during the period. Jane Street Group LLC raised its stake in shares of Certara by 17.1% during the 1st quarter. Jane Street Group LLC now owns 277,054 shares of the company’s stock valued at $2,743,000 after buying an additional 40,463 shares during the last quarter. Finally, TriaGen Wealth Management LLC purchased a new stake in shares of Certara in the second quarter worth about $475,000. Hedge funds and other institutional investors own 73.96% of the company’s stock.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.